← Eichor
Study identifier: NCT06467539 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Novel Augmentation of DAOIB and Antioxidant for Early Dementia

Condition: Alzheimer Disease · Mild Cognitive Impairment  ·  Sponsor: Chang Gung Memorial Hospital

PhasePhase 2
Planned participants80
Who can joinAll sexes, 50 Years to 90 Years
Healthy volunteersNo

About this study

Previous studies found that some NMDA-enhancing agents were able to improve cognitive function of patients with early-phase dementia. In addition, several drugs with antioxidant properties have been tested in clinical trials for the treatment of dementia too. Whether combined treatment of an NMDA-enhancing agent and a drug with antioxidant property can be better than an NMDA-enhancing agent alone deserves study.

This description comes directly from the study's public registry record.

Talk to the study team

Contact details are listed per location below or on the registry record.

Always discuss trial participation with your own doctor first.

Locations (1)

Chang Gung Memorial HospitalKaohsiung City, TaiwanRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06467539